Onco Therapies Ltd – wholly owned subsidiary of Strides Arcolab Ltd today said that it has received the US Food and Drug Administration’s (USFDA) approval for generic vinorelbine injection in 10 mg and 50 mg per ml dosage.
In a notice to the exchanges, Strides Arcolab said the product is available for immediate launch.
Vinorelbine, a chemotherapy drug, is used to treat various types of cancer. Vinorelbine is among the oncology products Strides Arcolab had licensed to Pfizer Inc for marketing in the US.
Strides Arcolab shares were closed at Rs. 820.8 on the National Stock Exchange in a choppy trading session.